Advertisement

Topics

ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

03:40 EST 18 Jan 2019 | Pharmaceutical Business Review

ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been

The post ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors appeared first on Pharmaceutical Business review.

Original Article: ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors

NEXT ARTICLE

More From BioPortfolio on "ADC doses first patient in phase I trial of ADCT-601 in advanced solid tumors"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...